CN Patent

CN111110681A — 喹啉衍生物联合卡培他滨在治疗肝癌的用途

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2020-05-08 · 6y expired

What this patent protects

本申请属于医药领域，提供一种喹啉衍生物联合卡培他滨在治疗肝癌的用途。本申请所提供的化合物I或其药学上可接受的盐以间隔给药的方式给药，联合卡培他滨节拍化疗，可用于治疗原发性肝癌，疗效评估结果表明原发性肝癌患者症状得到缓解，其总生存期得到延长。

USPTO Abstract

本申请属于医药领域，提供一种喹啉衍生物联合卡培他滨在治疗肝癌的用途。本申请所提供的化合物I或其药学上可接受的盐以间隔给药的方式给药，联合卡培他滨节拍化疗，可用于治疗原发性肝癌，疗效评估结果表明原发性肝癌患者症状得到缓解，其总生存期得到延长。

Drugs covered by this patent

Patent Metadata

Patent number
CN111110681A
Jurisdiction
CN
Classification
—
Expires
2020-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.